Prof. Mathias Mäurer discusses in this video about the new form of therapy and the current status of results on CAR-T cell therapy for MS. Please consider using the automated translation of YouTube. You can
Continue reading
Currently, reports from the UK are causing a stir. The reason is data from the British statistical authority, according to which there have been increasing deaths in connection with the intake of Pregabalin from 2018
Continue reading
This year’s annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place from October 12 to 14 in Milan. This most important scientific MS congress discusses the most important
Continue reading
Vidofludimus Calcium (IMU838) is a new, selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) from the biotech company Immunic Therapeutics. The manufacturer is currently testing it in patients with relapsing-remitting multiple sclerosis in a phase
Continue reading
Natalizumab (Tysabri®) inhibits the migration (transmigration) of inflammatory cells into the central nervous system and was the first monoclonal antibody approved for the treatment of relapsing multiple sclerosis.
Continue reading Cladribine is a prodrug, which is activated after being inserted into body cells and incorporated into the DNA of cells as a so-called nucleoside analogue. This integration leads to programmed cell death.
Continue reading
Autologous hematopoietic stem cell transplantation (AHSCT) is a topic of intense interest among patients. To explain briefly again: Autologous hematopoietic stem cell transplantation (AHSCT) is not about replacement or repair of nerve tissue. This possibility
Continue reading In view of practically relevant results from this year’s ECTRIMS meeting, I would like to emphasize studies on pregnancy and breastfeeding. B-cell-depleting therapies such as ocrelizumab and ofatumumab are often used in women of childbearing
Continue reading
There is news about Natalizumab (Tysabri®), which was expected, but it is still good that clarity now exists: In August 2021, the first results of the NOVA study were communicated, which compared the effectiveness of
Continue reading
These days, Ponvory® (Ponesimod), another drug from the group of S1P modulators for the treatment of relapsing MS, has arrived in pharmacies. This group includes, in addition to the “mother substance” Fingolimod, also Siponinmod and
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
